The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Open accessAbstract
Disease overview: Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding. An improved understanding of pathophysiology, improvements in measurement technology and at least 10 recently approved therapies have led to revamping the diagnostic, prognostic, and therapeutic landscape of AML. Diagnosis: One updated and one new classification system were published in 2022, both emphasizing the integration of molecular analysis into daily practice. Differences between the International Consensus Classification and major revisions from the previous 2016 WHO system provide both challenges and opportunities for care and clinical research. Risk assessment and monitoring: The European Leukemia Net 2022 risk classification integrates knowledge from novel molecular findings and recent trial results, as well as emphasizing dynamic risk based on serial measurable residual disease assessment. However, how to leverage our burgeoning ability to measure a small number of potentially malignant myeloid cells into therapeutic decision making is controversial. Risk adapted therapy: The diagnostic and therapeutic complexity plus the availability of newly approved agents requires a nuanced therapeutic algorithm which should integrate patient goals of care, comorbidities, and disease characteristics including the specific mutational profile of the patient's AML. The framework we suggest only represents the beginning of the discussion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 1×
“in the bone marrow or peripheral blood, any evidence of extramedullary myeloblasts (myeloid sarcoma), or presence of AML defining genetic abnormalities PML::RARA, RUNX1::RUNX1T1, and CBFB:: MYH11 irrespective of blast percentage.(42) Of note, Acute promyelocytic leukemia (APL), usually associated with a PML::RARA tran…”
BackgroundDöhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Self-citationAzacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationMohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S., Canin, B., Cohen, H. J., Holmes, H. M., Hopkins, J. O., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8687 · Cited by 1,479
Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Self-citationGilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Self-citationLancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,025
Self-citationCastaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Self-citationJuliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Koreth, J., Schlenk, R., Kopecky, K. J., Honda, S., Sierra, J., Djulbegovic, B. J., Wadleigh, M., DeAngelo, D. J., Stone, R. M., Sakamaki, H., et al. (2009) · JAMA · doi:10.1001/jama.2009.813 · Cited by 886
Self-citationAssessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Warrell, R. P., de The, H., Wang, Z.-Y., & Degos, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290307 · Cited by 776
Wei, A. H., Montesinos, P., Ivanov, V., DiNardo, C. D., Novak, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M., et al. (2020) · Blood · doi:10.1182/blood.2020004856 · Cited by 763
Heuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationDiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Yokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt-Rosen, O., Meyerson, M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 688
DiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 679
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y.-B., McSweeney, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 593
Pei, S., Pollyea, D. A., Gustafson, A., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0710 · Cited by 562
Burchert, A., Bug, G., Fritz, L. V., Finke, J., Stelljes, M., Röllig, C., Wollmer, E., Wäsch, R., Bornhäuser, M., Berg, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03345 · Cited by 555
Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., et al. (1981) · Blood · doi:10.1182/blood.v58.6.1203.1203 · Cited by 532
Schmid, C., Labopin, M., Nagler, A., Bornhäuser, M., Finke, J., Fassas, A., Volin, L., Gürman, G., Maertens, J., Bordigoni, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6053 · Cited by 516
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., Heuser, M., Calado, R. T., Schuh, A. C., Yeh, S.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117344 · Cited by 514
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Perl, A. E., Altman, J. K., Cortes, J., Smith, C., Litzow, M., Baer, M. R., Claxton, D., Erba, H. P., Gill, S., Goldberg, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30416-3 · Cited by 490
Wang, Y., Liu, Q.-F., Xu, L.-P., Liu, K.-Y., Zhang, X.-H., Ma, X., Fan, Z.-P., Wu, D.-P., & Huang, X.-J. (2015) · Blood · doi:10.1182/blood-2015-02-627786 · Cited by 486
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137345 · Cited by 475
Kim, M. Y., Yu, K.-R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T.-H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 459
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei, A. H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.-H., Porkka, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004444 · Cited by 445
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms
Polprasert, C., Schulze, I., Sekeres, M. A., Makishima, H., Przychodzen, B., Hosono, N., Singh, J., Padgett, R. A., Gu, X., Phillips, J. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.017 · Cited by 434
Klepin, H. D., Geiger, A. M., Tooze, J. A., Kritchevsky, S. B., Williamson, J. D., Pardee, T. S., Ellis, L. R., & Powell, B. L. (2013) · Blood · doi:10.1182/blood-2012-12-471680 · Cited by 426
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Short, N. J., Zhou, S., Fu, C., Berry, D. A., Walter, R. B., Freeman, S. D., Hourigan, C. S., Huang, X., Nogueras Gonzalez, G., Hwang, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4600 · Cited by 390
Platzbecker, U., Avvisati, G., Cicconi, L., Thiede, C., Paoloni, F., Vignetti, M., Ferrara, F., Divona, M., Albano, F., Efficace, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1982 · Cited by 389
Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., Altman, J. K., Arellano, M. L., Donnellan, W., Erba, H. P., et al. (2020) · Blood · doi:10.1182/blood.2019002140 · Cited by 381
Self-citationJw, Y., Hj, W., Rr, E., & Jf, H. (1973) · PubMed · Cited by 366
Schoch, C., Schnittger, S., Klaus, M., Kern, W., Hiddemann, W., & Haferlach, T. (2003) · Blood · doi:10.1182/blood-2003-02-0434 · Cited by 352
DiNardo, C. D., Lachowiez, C. A., Takahashi, K., Loghavi, S., Xiao, L., Kadia, T., Daver, N., Adeoti, M., Short, N. J., Sasaki, K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03736 · Cited by 331
Xuan, L., Wang, Y., Huang, F., Fan, Z., Xu, Y., Sun, J., Xu, N., Deng, L., Li, X., Liang, X., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30455-1 · Cited by 329
Sanz, M. A., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., de Lisa, E., Brunet, S., Rubio, V., Ribera, J. M., et al. (2010) · Blood · doi:10.1182/blood-2010-01-266007 · Cited by 328
Zhu, H.-H., Zhang, X.-H., Qin, Y.-Z., Liu, D.-H., Jiang, H., Chen, H., Jiang, Q., Xu, L.-P., Lu, J., Han, W., et al. (2013) · Blood · doi:10.1182/blood-2012-11-468348 · Cited by 327
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020007732 · Cited by 326
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772368 · Cited by 297
Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., & Kornblau, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.671 · Cited by 294
Schlenk, R. F., Weber, D., Fiedler, W., Salih, H. R., Wulf, G., Salwender, H., Schroeder, T., Kindler, T., Lübbert, M., Wolf, D., et al. (2019) · Blood · doi:10.1182/blood-2018-08-869453 · Cited by 290
Abaza, Y., Kantarjian, H., Garcia-Manero, G., Estey, E., Borthakur, G., Jabbour, E., Faderl, S., O’Brien, S., Wierda, W., Pierce, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736686 · Cited by 286
McDonald, G. B., Sandmaier, B. M., Mielcarek, M., Sorror, M., Pergam, S. A., Cheng, G.-S., Hingorani, S., Boeckh, M., Flowers, M. D., Lee, S. J., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-2936 · Cited by 285
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lee, L. Y., Hernandez, D., Rajkhowa, T., Smith, S. C., Raman, J. R., Nguyen, B., Small, D., & Levis, M. (2017) · Blood · doi:10.1182/blood-2016-10-745133 · Cited by 280
Sasaki, K., Ravandi, F., Kadia, T. M., DiNardo, C. D., Short, N. J., Borthakur, G., Jabbour, E., & Kantarjian, H. M. (2021) · Cancer · doi:10.1002/cncr.33458 · Cited by 276
Bornhäuser, M., Kienast, J., Trenschel, R., Burchert, A., Hegenbart, U., Stadler, M., Baurmann, H., Schäfer-Eckart, K., Holler, E., Kröger, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70349-2 · Cited by 274
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Lugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J. M., van Zelderen-Bhola, S. L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2771 · Cited by 256
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Mardiana, S., & Gill, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00697 · Cited by 236
Stein, E. M., DiNardo, C. D., Fathi, A. T., Mims, A. S., Pratz, K. W., Savona, M. R., Stein, A. S., Stone, R. M., Winer, E. S., Seet, C. S., et al. (2021) · Blood · doi:10.1182/blood.2020007233 · Cited by 232
Self-citationLancet, J. E., Uy, G. L., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., Bixby, D. L., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00134-4 · Cited by 230
Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S., & Keating, M. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229
The myth of the second remission of acute leukemia in the adult
Forman, S. J., & Rowe, J. M. (2013) · Blood · doi:10.1182/blood-2012-08-234492 · Cited by 225
Oran, B., de Lima, M., Garcia-Manero, G., Thall, P. F., Lin, R., Popat, U., Alousi, A. M., Hosing, C., Giralt, S., Rondon, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002544 · Cited by 219
Burnett, A. K., Goldstone, A., Hills, R. K., Milligan, D., Prentice, A., Yin, J., Wheatley, K., Hunter, A., & Russell, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5977 · Cited by 207
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, N., Perl, A. E., Maly, J., Levis, M., Ritchie, E., Litzow, M., McCloskey, J., Smith, C. C., Schiller, G., Bradley, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00602 · Cited by 200
Roboz, G. J., Rosenblat, T., Arellano, M., Gobbi, M., Altman, J. K., Montesinos, P., O'Connell, C., Solomon, S. R., Pigneux, A., Vey, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8562 · Cited by 198
Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R. A., Prior, T. W., Marcucci, G., Jones, D., Krauter, J., et al. (2020) · Blood · doi:10.1182/blood.2019002697 · Cited by 197
Self-citationDiNardo, C. D., Schuh, A. C., Stein, E. M., Montesinos, P., Wei, A. H., de Botton, S., Zeidan, A. M., Fathi, A. T., Kantarjian, H. M., Bennett, J. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00494-0 · Cited by 197
Genetic predisposition to hematologic malignancies: management and surveillance
Godley, L. A., & Shimamura, A. (2017) · Blood · doi:10.1182/blood-2017-02-735290 · Cited by 190
Stahl, M., Menghrajani, K., Derkach, A., Chan, A., Xiao, W., Glass, J., King, A. C., Daniyan, A. F., Famulare, C., Cuello, B. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003734 · Cited by 190
Self-citationChua, C. C., Roberts, A. W., Reynolds, J., Fong, C. Y., Ting, S. B., Salmon, J. M., MacRaild, S., Ivey, A., Tiong, I. S., Fleming, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00572 · Cited by 186
Kadia, T. M., Reville, P. K., Borthakur, G., Yilmaz, M., Kornblau, S., Alvarado, Y., Dinardo, C. D., Daver, N., Jain, N., Pemmaraju, N., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00192-7 · Cited by 181
McKoy, J. M., Angelotta, C., Bennett, C. L., Tallman, M. S., Wadleigh, M., Evens, A. M., Kuzel, T. M., Trifilio, S. M., Raisch, D. W., Kell, J., et al. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.005 · Cited by 180
Barbier, V., Erbani, J., Fiveash, C., Davies, J. M., Tay, J., Tallack, M. R., Lowe, J., Magnani, J. L., Pattabiraman, D. R., Perkins, A. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15817-5 · Cited by 180
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
Estey, E. H., Hasserjian, R. P., & Döhner, H. (2021) · Blood · doi:10.1182/blood.2021011304 · Cited by 180
Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01546 · Cited by 179
Ferrara, F., Barosi, G., Venditti, A., Angelucci, E., Gobbi, M., Pane, F., Tosi, P., Zinzani, P., & Tura, S. (2013) · Leukemia · doi:10.1038/leu.2012.303 · Cited by 178
The unique aspects of acute promyelocytic leukemia.
Stone, R. M., & Mayer, R. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1913 · Cited by 177
Self-citationClonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J., Skambraks, S., et al. (2021) · Blood · doi:10.1182/blood.2020007626 · Cited by 174
Self-citationPollyea, D. A., DiNardo, C. D., Arellano, M. L., Pigneux, A., Fiedler, W., Konopleva, M., Rizzieri, D. A., Smith, B. D., Shinagawa, A., Lemoli, R. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3467 · Cited by 169
Gooptu, M., Romee, R., St. Martin, A., Arora, M., Al Malki, M., Antin, J. H., Bredeson, C. N., Brunstein, C. G., Chhabra, S., Fuchs, E. J., et al. (2021) · Blood · doi:10.1182/blood.2021011281 · Cited by 168
Iland, H. J., Collins, M., Bradstock, K., Supple, S. G., Catalano, A., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Campbell, L. J., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00115-5 · Cited by 167
Othus, M., Kantarjian, H., Petersdorf, S., Ravandi, F., Godwin, J., Cortes, J., Pierce, S., Erba, H., Faderl, S., Appelbaum, F. R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.176 · Cited by 167
Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry
Wood, B. L. (2016) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21239 · Cited by 166
Levis, M. J., Perl, A. E., Altman, J. K., Gocke, C. D., Bahceci, E., Hill, J. E., Liu, C., Xie, Z., Carson, A. R., McClain, V., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015925 · Cited by 164
Parker, J. E., Pagliuca, A., Mijovic, A., Cullis, J. O., Czepulkowski, B., Rassam, S. M. B., Samaratunga, I. R., Grace, R., Gover, P. A., & Mufti, G. J. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4763281.x · Cited by 163
Kharfan-Dabaja, M. A., Labopin, M., Polge, E., Nishihori, T., Bazarbachi, A., Finke, J., Stadler, M., Ehninger, G., Lioure, B., Schaap, N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2091 · Cited by 162
Maziarz, R. T., Levis, M. J., Patnaik, M. M., Scott, B. L., Mohan, S. R., Deol, A., Rowley, S. D., Kim, D. D. H., Hernandez, D., Rajkhowa, T., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01153-1 · Cited by 162
Taube, F., Georgi, J. A., Kramer, M., Stasik, S., Middeke, J. M., Röllig, C., Krug, U., Krämer, A., Scholl, S., Hochhaus, A., et al. (2022) · Blood · doi:10.1182/blood.2020009680 · Cited by 162
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer · doi:10.1002/cncr.33689 · Cited by 161
Pollyea, D. A., Pratz, K. W., Wei, A. H., Pullarkat, V., Jonas, B. A., Recher, C., Babu, S., Schuh, A. C., Dail, M., Sun, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1183 · Cited by 159
Ganzel, C., Sun, Z., Cripe, L. D., Fernandez, H. F., Douer, D., Rowe, J. M., Paietta, E. M., Ketterling, R. P., O’Connell, M. J., Wiernik, P. H., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25162 · Cited by 159
Perl, A. E., Larson, R. A., Podoltsev, N. A., Strickland, S. A., Wang, E. S., Atallah, E. L., Schiller, G. J., Martinelli, G., Neubauer, A., Sierra, J., et al. (2022) · Blood · doi:10.1182/blood.2021011583 · Cited by 158
Wang, E. S., Montesinos, P., Minden, M. D., Lee, J., Heuser, M., Naoe, T., Chou, W., Laribi, K., Esteve, J., Altman, J. K., et al. (2022) · Blood · doi:10.1182/blood.2021014586 · Cited by 156
Lima, M. J. G. D., Oran, B., Champlin, R. E., Papadopoulos, E. B., Giralt, S. A., Scott, B. L., William, B. M., Hetzer, J., Laille, E. J., Hubbell, B., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.06.016 · Cited by 151
Gao, L., Zhang, Y., Wang, S., Kong, P., Su, Y., Hu, J., Jiang, M., Bai, H., Lang, T., Wang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03277 · Cited by 149
How I treat relapsed or refractory AML
DeWolf, S., & Tallman, M. S. (2020) · Blood · doi:10.1182/blood.2019001982 · Cited by 148
Stahl, M. F., DeVeaux, M., Montesinos, P., Itzykson, R., Ritchie, E. K., Sekeres, M. A., Barnard, J., Podoltsev, N. A., Brunner, A. M., Komrokji, R. S., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016121 · Cited by 146
Self-citationTargeting hedgehog in hematologic malignancy
Irvine, D. A., & Copland, M. (2012) · Blood · doi:10.1182/blood-2011-10-383752 · Cited by 145
Klepin, H. D., Geiger, A. M., Tooze, J. A., Kritchevsky, S. B., Williamson, J. D., Ellis, L. R., Levitan, D. A., Pardee, T. S., Isom, S. P., & Powell, B. L. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03614.x · Cited by 142
Röllig, C., Krämer, M., Schliemann, C., Mikesch, J., Steffen, B., Krämer, A., Noppeney, R., Schäfer‐Eckart, K., Krause, S. W., Hänel, M., et al. (2020) · Blood · doi:10.1182/blood.2019004583 · Cited by 140
Wang, H., Mao, L., Yang, M., Qian, P., Lu, H., Tong, H., Xie, W., Zhou, D., Huang, X., Wang, Y., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00106-5 · Cited by 138
Rashidi, A., Hamadani, M., Zhang, M., Wang, H.-L., Abdel‐Azim, H., Aljurf, M. D., Assal, A., Bajel, A. R., Bashey, A., Battiwalla, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000050 · Cited by 130
Kadia, T. M., Reville, P. K., Wang, X., Rausch, C. R., Borthakur, G. M., Pemmaraju, N., Daver, N. G., Dinardo, C. D., Sasaki, K., Issa, G. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02823 · Cited by 129
Watts, J. M., Baer, M. R., Yang, J., Prébet, T., Lee, S., Schiller, G. J., Dinner, S. N., Pigneux, A., Montesinos, P., Wang, E. S., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00292-7 · Cited by 129
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Luskin, M. R., Lee, J., Fernandez, H. F., Abdel-Wahab, O. I., Bennett, J. M., Ketterling, R. P., Lazarus, H. M., Levine, R. L., Litzow, M. R., Paietta, E. M., et al. (2016) · Blood · doi:10.1182/blood-2015-07-657403 · Cited by 128
Rücker, F. G., Agrawal, M., Corbacioglu, A., Weber, D., Kapp‐Schwoerer, S., Gaidzik, V. I., Jahn, N., Schroeder, T. A., Wattad, M. A., Lübbert, M., et al. (2019) · Blood · doi:10.1182/blood.2019001425 · Cited by 128
Tarlock, K., Lamble, A. J., Wang, Y., Gerbing, R. B., Ries, R. E., Loken, M. R., Brodersen, L. E., Pardo, L. M., Leonti, A. R., Smith, J. L., et al. (2021) · Blood · doi:10.1182/blood.2020009652 · Cited by 126
Norsworthy, K. J., Mulkey, F. A., Scott, E., Ward, A. F., Przepiorka, D., Charlab, R., Dorff, S. E., Deisseroth, A., Kazandjian, D. G., Sridhara, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0834 · Cited by 120
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
Wakita, S., Sakaguchi, M., Oh, I., Kako, S., Toya, T., Najima, Y., Doki, N., Kanda, J., Kuroda, J., Mori, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004292 · Cited by 117
Angenendt, L., Röllig, C., Montesinos, P., Martínez‐Cuadrón, D., Barragán, E., García, R., Botella, C., Martı́nez, P., Ravandi, F., Kadia, T. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00416 · Cited by 116
Schlenk, R. F., Paschka, P., Krzykalla, J., Weber, D., Kapp‐Schwoerer, S., Gaidzik, V. I., Leis, C., Fiedler, W., Kindler, T., Schroeder, T. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01406 · Cited by 115
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Matthews, A. H., Perl, A. E., Luger, S. M., Loren, A. W., Gill, S. I., Porter, D. L., Babushok, D. V., Maillard, I. P., Carroll, M. P., Frey, N. V., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007265 · Cited by 112
Yang, F., Long, N., Anekpuritanang, T., Bottomly, D., Savage, J. C., Lee, T. L., Solis-Ruiz, J. M., Borate, U., Wilmot, B., Tognon, C. E., et al. (2021) · Blood · doi:10.1182/blood.2021011354 · Cited by 107
Dinardo, C. D., Lachowiez, C. A., Takahashi, K., Loghavi, S., Kadia, T. M., Daver, N. G., Xiao, L., Adeoti, M., Short, N. J., Sasaki, K., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26601 · Cited by 106
Venugopal, S., Takahashi, K., Daver, N. G., Maiti, A., Borthakur, G. M., Loghavi, S., Short, N. J., Ohanian, M. N., Masárová, L., Issa, G. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00604-2 · Cited by 103
DeAngelo, D. J., Jonas, B. A., Liesveld, J. L., Bixby, D. L., Advani, A. S., Marlton, P. V., Magnani, J. L., Thackray, H. M., Feldman, E. J., O'Dwyer, M. E., et al. (2021) · Blood · doi:10.1182/blood.2021010721 · Cited by 96
Pollyea, D. A., Winters, A. C., McMahon, C. M., Schwartz, M., Jordan, C. T., Rabinovitch, R. A., Abbott, D., Smith, C. A., & Gutman, J. A. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01476-7 · Cited by 96
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
Guy, D. G., & Uy, G. L. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0472-8 · Cited by 92
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Fournier, É., Duployez, N., Ducourneau, B., Raffoux, E., Turlure, P., Caillot, D., Thomas, X., Marceau‐Renaut, A., Chantepie, S., Malfuson, J., et al. (2019) · Blood · doi:10.1182/blood.2019003471 · Cited by 92
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms
Li, P., Brown, S., Williams, M., White, T., Xie, W., Cui, W., Peker, D., Lei, L., Kunder, C. A., Wang, H., et al. (2022) · Blood · doi:10.1182/blood.2021015135 · Cited by 92
Duployez, N., Largeaud, L., Duchmann, M., Kim, R., Rieunier, J., Lambert, J., Bidet, A., Larcher, L., Lemoine, J., Delhommeau, F., et al. (2022) · Blood · doi:10.1182/blood.2021015328 · Cited by 87
Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Wulf, G. G., Salih, H. R., Lübbert, M., Kühn, M. W. M., Schroeder, T. A., Salwender, H. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007223 · Cited by 86
Self-citationMin, G. J., Cho, B., Park, S., Park, S., Jeon, Y., Shin, S., Yahng, S., Yoon, J., Lee, S.-E., Eom, K., et al. (2022) · Blood · doi:10.1182/blood.2021013671 · Cited by 76
Lancet, J. E., Moseley, A. B., Coutre, S. E., DeAngelo, D. J., Othus, M. K. D., Tallman, M. S., Litzow, M. R., Komrokji, R. S., Erba, H. P., & Appelbaum, F. R. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001278 · Cited by 73
Dinardo, C. D., Garcia‐Manero, G., Pierce, S. A., Nazha, A., Bueso-Ramos, C., Jabbour, E. J., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24252 · Cited by 70
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel, S. S., Ho, C., Ptashkin, R. N., Sadigh, S., Bagg, A., Geyer, J. T., Xu, M. L., Prébet, T., Mason, E. F., Seegmiller, A. C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000090 · Cited by 69
Daver, N. G., Konopleva, M. Y., Maiti, A., Kadia, T. M., Dinardo, C. D., Loghavi, S., Pemmaraju, N., Jabbour, E. J., Bravo, G. M., Tang, G., et al. (2021) · Blood · doi:10.1182/blood-2021-153638 · Cited by 69
Robak, T., Wrzesień‐Kuś, A., Lech‐Marańda, E., Kowal, M., & Dmoszyńska, A. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009053545 · Cited by 68
Brunner, A. M., Esteve, J., Porkka, K., Knapper, S., Vey, N., Scholl, S., Garcia‐Manero, G., Wermke, M., Janssen, J., Traer, E. A., et al. (2020) · Blood · doi:10.1182/blood-2020-136855 · Cited by 68
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
Rautenberg, C., Stölzel, F., Röllig, C., Stelljes, M., Gaidzik, V. I., Lauseker, M., Kriege, O., Verbeek, M., Unglaub, J. M., Thol, F. R., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00558-5 · Cited by 68
DuMontier, C., Uno, H., Hshieh, T. T., Zhou, G., Chen, R., Magnavita, E. S., Mozessohn, L., Javedan, H., Stone, R. M., Soiffer, R. J., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278802 · Cited by 62
Self-citationWeisberg, E., Meng, C., Case, A. E., Sattler, M., Tiv, H. L., Gokhale, P. C., Buhrlage, S. J., Liu, X., Yang, J. C., Wang, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16092 · Cited by 58
Self-citationPalmieri, R., Othus, M. K. D., Halpern, A. B., Percival, M. M., Godwin, C. D., Becker, P. S., & Walter, R. B. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01392 · Cited by 56
Garcia, J. S., Kim, H. T., Murdock, H. M., Cutler, C. S., Brock, J., Gooptu, M., Ho, V. T., Koreth, J., Nikiforow, S., Romee, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005566 · Cited by 54
Self-citationNuman, Y., Rahman, Z. A., Grenet, J. E., Boisclair, S., Bewersdorf, J. P., Collins, C. T., Barth, D. M., Fraga, M. S., Bixby, D. L., Zeidan, A. M., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26447 · Cited by 52
Halpern, A. B., Othus, M. K. D., Huebner, E. M., Scott, B. L., Becker, P. S., Percival, M. M., Hendrie, P. C., Gardner, K. M., Chen, T. L., Buckley, S. A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0135-8 · Cited by 49
Hereditary myeloid malignancies
Rafei, H., & Dinardo, C. D. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.001 · Cited by 49
Maiti, A., Dinardo, C. D., Qiao, W., Kadia, T. M., Jabbour, E. J., Rausch, C. R., Daver, N. G., Short, N. J., Borthakur, G. M., Pemmaraju, N., et al. (2021) · Cancer · doi:10.1002/cncr.33814 · Cited by 49
Sequencing-based measurable residual disease testing in acute myeloid leukemia
Yoest, J. M., Shirai, C. L., & Duncavage, E. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00249 · Cited by 48
Daver, N. G., Vyas, P., Kambhampati, S., Malki, M. M. A., Larson, R. A., Asch, A. S., Mannis, G. N., Chai‐Ho, W., Tanaka, T. N., Bradley, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.7020 · Cited by 47
Quantification of rare NPM 1 mutation subtypes by digital PCR
Bacher, U., Dicker, F., Haferlach, C., Alpermann, T., Rose, D., Kern, W., Haferlach, T., & Schnittger, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13038 · Cited by 43
Lindsley, R. C., Gibson, C. J., Murdock, H. M., Stone, R. M., Cortes, J. E., Uy, G. L., Lin, T. L., Ritchie, E. K., Prébet, T., Ryan, R. J., et al. (2019) · Blood · doi:10.1182/blood-2019-124500 · Cited by 42
Self-citationNPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., Riva, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238975 · Cited by 42
Pigneux, A., Béné, M. C., Salmi, L., Dumas, P., Delaunay, J., Bonmati, C., Guièze, R., Luquet, I., Cornillet‐Lefèbvre, P., Delabesse, É., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.7366 · Cited by 41
Ritchie, E. K., Klepin, H. D., Storrick, E. M., Major, B. T., Le‐Rademacher, J. G., Wadleigh, M., Walker, A., Larson, R. A., & Roboz, G. J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006872 · Cited by 40
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia
Cortes, J. E., & Mehta, P. (2020) · American Journal of Hematology · doi:10.1002/ajh.26079 · Cited by 37
Pasvolsky, O., Shimony, S. O., Ram, R., Shimoni, A., Shargian, L., Avni, B. R., Wolach, O., Shochat, T., Yerushalmi, R., Amit, O., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04693-8 · Cited by 37
Self-citationKäyser, S., Hills, R. K., Langova, R., Krämer, M., Guijarro, F., Šustková, Z., Estey, E. H., Shaw, C. M., Ráčil, Z., Mayer, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17336 · Cited by 35
Trottier, A. M., & Godley, L. A. (2020) · British Journal of Haematology · doi:10.1111/bjh.17247 · Cited by 31
Wolach, O., Frisch, A., Shargian, L., Yeshurun, M., Apel, A., Vainstein, V., Moshe, Y., Shimony, S. O., Amit, O., On, Y. B., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04883-y · Cited by 31
Self-citationShallis, R. M., Pollyea, D. A., & Zeidan, A. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100806 · Cited by 26
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
Shimony, S. O., Stone, R. M., & Stahl, M. F. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000698 · Cited by 25
Self-citationShimony, S. O., Canaani, J., Kugler, E., Nachmias, B., Ram, R., Henig, I. J., Frisch, A., Ganzel, C., Vainstein, V., Moshe, Y., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04895-8 · Cited by 23
Self-citationLancet, J. E., Uy, G. L., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., Solomon, S. R., Bixby, D. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.7510 · Cited by 22
Time to blur the blast boundaries
Dinardo, C. D., Garcia‐Manero, G., & Kantarjian, H. M. (2022) · Cancer · doi:10.1002/cncr.34119 · Cited by 20
Pasvolsky, O., Shimony, S. O., Yeshurun, M., Shargian, L., Wolach, O., Raanani, P., Gafter‐Gvili, A., & Gurion, R. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1955969 · Cited by 16
Self-citationRussell, N. H., Hills, R. K., Kjeldsen, L., Dennis, M., & Burnett, A. K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17974 · Cited by 16
Cited by
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Hossen, M. A., Jahan, U. M. S., Hossain, M. A., Asif, K. H., Rahman, A., Ahmed, S., Uddin, M. M., Amin, M. F., Barik, M. A., Islam, M. J., et al. (2025) · PLOS One · doi:10.1371/journal.pone.0320550 · Cited by 8
Metadata
- Authors
- Shimony, S., Stahl, M., & Stone, R. M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2023-01-13
- Volume
- 98
- Issue
- 3
- Pages
- 502-526
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W4313454313
- Cited by
- 448
- References
- 177
- FWCI
- 81.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.